Journal Club - Low dose atropine has been found to be effective in treating myopia

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2022-05-09 04:15 GMT | Update On 2022-05-09 04:15 GMT

Previous reviews and meta-analyses reported that among various treatment options available, topical atropine shows a maximum reduction in myopia progression. A recent Study in Scientific Reports has evaluated the efficacy and safety of low-dose atropine compared to placebo in the Indian population and also to study the impact of various modifiable and non-modifiable factors on myopia progression (MP) and drug efficacy (DE).

The Study was a single-centred prospective placebo-controlled interventional study, which included a total of 43 participants aged 6–16 years with progressive myopia. All the participants received 0.01% atropine in the right eyes (treatment) and placebo in the left eyes (control) for 1-year. The main outcome measures were annual myopia progression and axial length elongation (ALE) in treatment and control eyes and their drug efficacy.

It was then found that, myopia progression showed 63.89% reduction with respective axial length elongation at 44.44% reduction. Reduction in both the parameters was statistically significant in all children irrespective of age-group, baseline MP, family history, screen- time, near and outdoor-time. The researchers concluded that 0.01% atropine was effective and safe in retarding myopia progression and axial length elongation in Indian eyes, lifestyle and habits might also have a crucial role to play in it.

We now have with us, the lead author of this study, Dr. Shweta Chaurasia, Assistant Professor at the Advanced Eye Centre, PGIMER Chandigarh.

Full View

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Nandita Mohan

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Journal Club - Low dose atropine has been found to be effective in treating myopia

Similar News

AI-Powered Eye Scan Predicts Dementia Risk Years Before Symptoms: Study Finds

Omega-3-Rich Diet Help Protect Children Against Nearsightedness: Study Finds

Can Just an Hour of Scrolling Reels Lead to Eye Strain? Study Provides Insights

Surgical Implant Slows Vision Loss in Rare Eye Disease: NEJM Evidence Study

WHO Issues Safety Over Rare Eye Disorder from Semaglutide Use

Diabetes and Weight-Loss Drug Semaglutide Linked to Rare Eye Condition: European Medical Agency

Fear of Vision Loss May Delay Cataract Surgery: Study Finds

BRESER Study Demonstrates Real-World Efficacy and Safety of Lupin's Ranibizumab Biosimilar (Ranieyes)